NCT04810052
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must self-identify as ethnically one of the 4 ethnic groups of focus: Asian American, African American, Latino, & European American
Exclusions: Patients with life expectancy less than 6 months in the opinion of the primary physician
https://ClinicalTrials.gov/show/NCT04810052